News Detail

Marcy-l’Étoile (France), 31 March 2024: BioMérieux announced today that its Biofire Spotfire Respiratory/Sore Throat (R/ST) Panel has received dual U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CL......
View Details
Source : Lab Pulse
FDA
USFDA
bioMérieux
sore throat
respiratory infection
pharyngitis syndrome
respiratory tract infection
biofire
spotfire
Related News
- Critical medicines for cancer, diabetes set to get expensive as govt clears price hike, say sources (27-03-2025)
- DGFT proposes mandatory GST E-Invoices for pharma export benefits (27-03-2025)
- US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome (27-03-2025)
- FDA approves GSK’s 'Blujepa' for uncomplicated UTIs (27-03-2025)
- Bengal drug control publishes helpline to report fake medicines (27-03-2025)
- Misleading ads: SC asks states UTs to set up grievance redressal mechanism (26-03-2025)
- WHO partners with regulators, experts to strengthen safety and access of medical devices (26-03-2025)
- PCI warns of tough action against inspectors who don't follow its guidelines during inspection (26-03-2025)
- Seizure of fake Human Albumin Vials rings alarm bells (26-03-2025)
- Pharmacy owner, three others held for illegal sale of intoxication drug (26-03-2025)